Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELOX Stock Price Chart Interactive Chart >
ELOX Price/Volume Stats
| Current price | $3.41 | 52-week high | $40.40 |
| Prev. close | $3.57 | 52-week low | $3.30 |
| Day low | $3.41 | Volume | 15,690 |
| Day high | $3.63 | Avg. volume | 6,744 |
| 50-day MA | $5.72 | Dividend yield | N/A |
| 200-day MA | $11.90 | Market Cap | 7.39M |
Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.
Latest ELOX News From Around the Web
Below are the latest news stories about ELOXX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELOX as an investment opportunity.
Eloxx Pharmaceuticals GAAP EPS of -$0.09
|
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business UpdateStarted proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells by the end of 2022 or early 2023 WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted gen |
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport SyndromeTrial sites now open in Australia and the United KingdomWATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites for its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. “Rare diseases with nonsense mutations, such as Alport syndrome, are particularly challenging to treat. We are incredi |
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet GoalEloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
ELOX Price Returns
| 1-mo | -39.11% |
| 3-mo | -75.64% |
| 6-mo | -71.58% |
| 1-year | -88.24% |
| 3-year | -98.34% |
| 5-year | -98.87% |
| YTD | -87.93% |
| 2021 | -82.26% |
| 2020 | -45.92% |
| 2019 | -38.72% |
| 2018 | 50.13% |
| 2017 | 185.31% |
Loading social stream, please wait...